In conclusion, based on available data, upfront autoSCT should be recommended as a rational choice for patients with the nodal subtypes PTCL-NOS, AITL, ALK-negative ALCL, as well as high-risk ALK-positive ALCL eligible for high-dose chemotherapy.5 However, PFS remains disappointing ranging from 30 to 50%. This evidence concerns the gene ALK and anaplastic large cell lymphoma.